|
Contents
|
|
|
|
Brain
Tumors
|
|
|
|
|
Jakacki RI, Hamilton M, Gilbertson RJ, Blaney
SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC
Pediatric phase I and pharmacokinetic study of erlotinib followed by the
combination of erlotinib and temozolomide: a Children's Oncology Group Phase
I Consortium Study
J
Clin Oncol. 2008 Oct 20;26(30):4921-7.
Epub 2008 Sep 15
.JPG)
Abstract
|
|
|
Glioblastoma
|
|
|
|
|
Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle
KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton
RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C,
Buckner JC
Phase I/II Trial Erlotinib and Temozolomide With Radiation Therapy in the
Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer
Treatment Group Study N0177
J
Clin Oncol. 2008 Oct 27. [Epub ahead of print]
Abstract
|
|
|
Halatsch
ME, Löw S, Hielscher T, Schmidt U, Unterberg A, Vougioukas VI
Epidermal growth factor receptor pathway gene expressions and biological
response of glioblastoma multiforme cell lines to erlotinib
Anticancer Res. 2008 Nov-Dec;28(6A):3725-8
Abstract
|
|
S. Krishnan, P.
Brown, K. Ballman, J. Fiveash, J.
Uhm, C. Giannini, F. Geoffroy, L.
Nabors and J. Buckner
Phase I trial of erlotinib with
radiation therapy (RT) in patients with glioblastoma multiforme (GBM)
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1513.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1513
|
|
|
Löw S, Vougioukas VI, Hielscher T, Schmidt U, Unterberg A, Halatsch
ME
Pathogenetic pathways leading to glioblastoma multiforme: association
between gene expressions and resistance to erlotinib
Anticancer Res. 2008 Nov-Dec;28(6A):3729-32
Abstract
|
|
|
Peereboom
DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms
SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH
Phase II trial of erlotinib with temozolomide and radiation in patients
with newly diagnosed glioblastoma multiforme
J Neurooncol.
2009 Dec 4. [Epub ahead of print]
Abstract | .png)
Full Text | .png)
Reprint
|
|
|
Prados MD, Chang SM, Butowski N, Deboer R,
Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M,
Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James
CD, Lamborn KR, Stokoe D, Haas-Kogan DA
Phase
II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy
in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
J
Clin Oncol. 2008 Dec 15. [Epub ahead of print]
Abstract
|
|
Recurrent
Tumors
|
|
|
|
de Groot JF, Gilbert MR, Aldape K, Hess KR,
Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V,
Yung WK
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in
patients with recurrent glioblastoma
J Neurooncol. 2008 Jun 26; [Epub ahead of print]
Abstract
|
|
T. Cloughesy, A. Yung,
J. Vrendenberg, K. Aldape, D. Eberhard,
M. Prados, S. Vandenberg, B. Klencke
and P. Mischel
Phase II study of erlotinib in recurrent GBM: Molecular predictors of
outcome
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1507.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1507
|
|
|
Reardon DA, Desjardins A, Vredenburgh JJ,
Gururangan S, Friedman AH, Herndon JE 2nd, Marcello J, Norfleet JA, McLendon
RE, Sampson JH, Friedman HS
Phase
2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
J Neurooncol.
2009 Jun 28. [Epub ahead of print]
Abstract
|
|
|
van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier
AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ,
Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T
Randomized
Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent
Glioblastoma: EORTC Brain Tumor Group Study 26034
J
Clin Oncol. 2009 Feb 9. [Epub ahead of print]
Abstract
|
|
M. A. Vogelbaum, D. Peereboom, G.
Stevens, G. Barnett, C. Brewer
Phase II trial of the EGFR tyrosine kinase
inhibitor erlotinib for single agent therapy of recurrent Glioblastoma
Multiforme: Interim results
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1558
|
|
A. Yung, J. Vredenburgh, T.
Cloughesy, B. J. Klencke, P. S. Mischel, D. D. Bigner, K. Aldape, S. Vanderburg,
M. Prados, The Accelerate Brain Cancer Cure Group
Erlotinib HCL for glioblastoma multiforme in first
relapse, a phase II trial
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1555
|
|
|
Yung
WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR,
Reardon DA, Prados MD.
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II
open-label study
Neuro Oncol. 2010 Jul 8;. [Epub ahead of print]
Abstract
|
|
|
Gliomas
|
|
|
|
|
Brandes AA, Franceschi E, Tosoni A, Hegi ME,
Stupp R
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and
disappointments
Clin
Cancer Res. 2008 Feb 15;14(4):957-60
Abstract
|
|
|
Broniscer A, Baker SJ, Stewart CF, Merchant TE, Laningham FH, Schaiquevich
P, Kocak M, Morris EB, Endersby R, Ellison DW, Gajjar A
Phase
I and pharmacokinetic studies of erlotinib administered concurrently with
radiotherapy for children, adolescents, and young adults with high-grade
glioma
Clin
Cancer Res. 2009 Jan 15;15(2):701-7
Abstract
|
|
Lassman AB, Rossi MR, Razier JR, Abrey LE,
Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ,
Cowell JK, Deangelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland
EC
Molecular study of malignant
gliomas treated with epidermal growth factor receptor inhibitors: tissue
analysis from north american brain tumor consortium trials 01-03 and 00-01
Clin
Cancer Res. 2005 Nov 1;11(21):7841-50
|
|
M.
Prados, S. Chang, E. Burton, A. Kapadia, J. Rabbitt, M. Page, A. Federoff,
S. Kelly, G. Fyfe
Phase I study of OSI-774 alone or with temozolomide in
patients with malignant glioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No. 394
|
|
Recurrent
Tumors
|
|
|
|
Geoerger
B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts
I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C,
Leblond P, Morland B, Gentet JC, Méresse V, Vassal G.
Innovative Therapies for Children with Cancer pediatric phase I study of
erlotinib in brainstem glioma and relapsing/refractory brain tumors.
Neuro Oncol. 2010 Oct 25;. [Epub ahead of print]
Abstract |
.gif)
Related articles
|
|
J. J. Raizer, L. E. Abrey, P. Wen,
T. Cloughesy, I. A. Robins, H. A. Fine, F. Lieberman, V. K. Puduvalli, K. L.
Fink, M. Prados
A phase II trial of erlotinib (OSI-774) in patients
(pts) with recurrent malignant gliomas (MG) not on EIAEDs
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1502
|
|
|
Sathornsumetee
S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe
A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA.
Phase II trial of bevacizumab and erlotinib in patients with recurrent
malignant glioma
Neuro Oncol. 2010 Aug 17;. [Epub ahead of print]
Abstract
|
|
|
Hemangioblastoma
|
|
|
|
Lisa
R Rogers, William Kaelin, Paul Nadler, Anthony F Shields, Patricia LoRusso
Response
of cerebellar hemangioblastomas associated with von Hippel-Lindau disease to
OSI-774 (TarcevaTM)
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
2111
|
|
|
Meningioma |
|
|
|
|
Norden AD, Raizer JJ, Abrey LE, Lamborn KR,
Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM,
Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY
Phase
II trials of erlotinib or gefitinib in patients with recurrent meningioma
J Neurooncol.
2009 Jun 28. [Epub ahead of print]
Abstract
|
|
|
Metastatic
Tumors |
|
|
|
|
Altavilla G, Arrigo C, Santarpia MC, Galletti G,
Picone G, Marabello G, Tomasello C, Pitini VV
Erlotinib therapy in a patient with non-small-cell lung cancer and brain
metastases
J Neurooncol.
2008 Jun 20. [Epub ahead of print]
Abstract
|
|
|
Costa DB, Kobayashi S
Response of intracranial metastases to epidermal growth factor receptor
tyrosine kinase inhibitors: it may all depend on EGFR mutations
J
Clin Oncol. 2008 Feb 1;26(4):686.
Abstract |
Full Text |
Reprint
|
|
|
Fekrazad MH, Ravindranathan M, Jones DV Jr.
Response of intracranial metastases to erlotinib therapy
J
Clin Oncol. 2007 Nov 1;25(31):5024-6
Abstract |
Full Text |
Reprint
|
|
|
Lind JS, Lagerwaard FJ, Smit EF, Senan S
Phase
I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple
Brain Metastases from Non-Small-Cell Lung Cancer
Int
J Radiat Oncol Biol Phys. 2009 Mar 14. [Epub ahead of print]
Abstract
|
|
|
Olmez I, Donahue BR, Butler JS, Huang Y, Rubin
P, Xu Y.
Clinical outcomes in extracranial tumor sites and unusual toxicities with
concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients
with non-small cell lung cancer (NSCLC) with brain metastasis
Lung Cancer. 2010 Mar 5;. [Epub ahead of print]
Abstract
|
|
Lung
Cancer
|
|
|
|
Zhao
J, Fu Q, Zhang L.
A Clinical Observation of Concomitant Therapy of Erlotinib and Whole Brain
Radiotherapy in Patients of NSCLC Combined with Brain Metastases
Zhongguo Fei Ai Za Zhi (Chinese Journal of Lung Cancer). 2009 Dec
20;12(12):1291-4. Chinese
Abstract
|
Full
Text |
Reprint
|
|
|
|
